| Current Price | $183.52 | Mkt Cap | $47.6B |
|---|---|---|---|
| Open | $186.77 | P/E Ratio | 23.90 |
| Prev. Close | $183.52 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $182.88 - $187.15 | Volume | 1,945,186 |
| 52-Wk Range | $176.36 - $242.99 | Avg. Daily Vol. | 1,463,101 |
The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.
| Current Price | $183.52 | Mkt Cap | $47.6B |
|---|---|---|---|
| Open | $186.77 | P/E Ratio | 23.90 |
| Prev. Close | $183.52 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $182.88 - $187.15 | Volume | 1,945,186 |
| 52-Wk Range | $176.36 - $242.99 | Avg. Daily Vol. | 1,463,101 |
The best Bull and Bear pitches based on recency and number of recommendations.
-Bullishness on gene therapy segment and partnership w/ CRISPR-Strength in Cystic Fibrosis treatment (Dominant, but large part of US TAM left to capture)-Research methodology/product development strategy-Current valuation and multiples. ($55Bn,… More
9/26/14 DOWN TO UP = <30.04> 7/19/16 = UP TO DOWN
Read the most recent pitches from players about VRTX.
Recs
wrciii
(87.21)
Submitted: 9/20/2021 11:17:23 AM :
Start Price:
$187.57
NASDAQ:VRTX Score:
-6.28
Salveen
Recs
XMFFlygal
(99.49)
Submitted: 8/23/2021 9:31:56 PM :
Start Price:
$231.00
NASDAQ:VRTX Score:
-43.68
Product revenues of $1.79 billion, an 18% increase compared to Q2 2020
In the second quarter of 2021, we saw continued, significant growth and strong business performance in our cystic fibrosis franchise. We have now secured reimbursement agreements for the triple combination in more than 15 countries outside the U.S. and started expansion into younger age groups with the U.S. approval in patients 6 to 11 years of age last month. With these advancements, we are poised to reach more patients in 2021 than previously forecasted and are therefore raising our 2021 revenue guidance. Looking forward, we continue to see significant growth ahead in CF, with more than 30,000 CF patients who may benefit from the triple combination but who are not yet treated,
Recs
Car12703
(46.82)
Submitted: 8/9/2021 10:18:37 AM :
Start Price:
$199.83
NASDAQ:VRTX Score:
-10.63
From Fidelity August 2021:
Revenue Growth (Last 5 Years) = 43.2%
Revenue % Change (Last Qrtr VS. Same Qrtr Prior Year) = 17.6%
Price/Sales (TTM) = 7.8
Find the members with the highest scoring picks in VRTX.
dmcnic (61.95) Score: +931.18
The Score Leader is the player with the highest score across all their picks in VRTX.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| bugeyebear | 30.94 | 3/17/2008 |
|
3Y | $14.60 | +1,158.63% | +269.96% | +888.67 | 0 Comment | |
| lostontheprairie | 68.06 | 3/12/2008 |
|
5Y | $14.99 | +1,125.88% | +255.79% | +870.09 | 0 Comment | |
| Kudude | 60.71 | 3/12/2008 |
|
5Y | $14.99 | +1,125.88% | +255.79% | +870.09 | 0 Comment | |
| Salilp | 73.84 | 3/17/2008 |
|
5Y | $15.07 | +1,119.38% | +273.12% | +846.26 | 0 Comment | |
| davidmouw2 | < 20 | 3/14/2008 |
|
NS | $15.43 | +1,090.93% | +255.69% | +835.24 | 0 Comment | |
|
snazzysnazz | 72.17 | 3/13/2008 |
|
5Y | $15.49 | +1,086.31% | +264.38% | +821.93 | 0 Comment |
| NovaMechanika | 20.30 | 3/20/2008 |
|
3Y | $15.55 | +1,081.74% | +261.36% | +820.38 | 2 Comments | |
| stnewbie | 39.31 | 3/12/2008 |
|
NS | $15.78 | +1,064.51% | +257.41% | +807.10 | 0 Comment | |
| PrincetonAl | 88.75 | 3/7/2008 |
|
3Y | $15.86 | +1,058.64% | +264.32% | +794.32 | 1 Comment | |
|
|
hayrettin | 72.70 | 3/24/2008 |
|
5Y | $16.47 | +1,015.73% | +252.51% | +763.21 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
